Chamber and committees

The following table provides a breakdown of the core activity undertaken at the National Eye Centre at NHS Golden Jubilee, by month, since it opened in November 2020 up to the end of June 2022.

This does not include activity undertaken in main theatres at the NHS Golden Jubilee University National Hospital in 2020-21 prior to the National Eye Centre opening, nor any activity carried out in the National Eye Centre as part of the current independent sector contracts.

Scottish Government officials are meeting with NHS Education Scotland on 27 September to explore primary care cancer education. This follows the recent cessation of Cancer Research UK’s Clinical Engagement Team that played a key role in delivering cancer education across NHS Scotland in recent years.

I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

My intention is to update Parliament with our Winter Resilience plans and publish our Winter Resilience Overview, covering both the NHS and Social Care, early next month, subject to discussions at Parliamentary Bureau. Caroline Lamb, CEO of NHS Scotland has also already written to NHS Boards and Integration Authorities regarding winter resilience plans at a national level and setting out clear expectations for local resilience and response.

The Scottish Government has had very constructive discussions with AstraZeneca on Evusheld ® for the preventative treatments for COVID-19. However, throughout the pandemic, a UK-wide approach to the procurement of therapeutics has been taken and has proven vital to allow the UK to have the buying power to secure significant numbers of therapeutics in a competitive global market. A UK-wide approach has also been taken on the development and implementation of clinical prescribing policies for COVID-19 therapeutics. This has ensured patients across the UK have had equal access to safe and effective medicines for COVID-19.

The Scottish Medicines Consortium (SMC) is a partner in a UK-wide multi-agency RAPID C-19 initiative, which is a collaborative partnership between the SMC and the National Institute for Health and Care Excellence (NICE). Building on this work, the SMC is exploring the potential for collaboration with NICE on a single technology assessment (STA) of tixagevimab–cilgavimab (Evusheld ® ) for the prevention of COVID-19.

As part of the Scottish Medicines Consortium’s (SMC) continuing role in the UK-wide multi-agency RAPID C-19 initiative, the collaborative partnership between the SMC and the National Institute for Health and Care Excellence (NICE) will extend to the multiple technology assessment (MTA) of the range of therapeutics for the treatment of COVID-19; therefore, a separate assessment of these medicines by the SMC will not be required.

The questions used in the next Scottish Cancer Patient Experience Survey will be relevant to all cancer patients including those with blood cancer. The data collected will be broken down by cancer type and published as it has been in previous years.

Despite the continued and unprecedented challenges presented by the COVID-19 pandemic, the Scottish Stroke Improvement Programme report, published on 28 June, highlights areas where a high level of care is provided for stroke patients, including improvements in the number of patients who receive brain imagining within 12 hours of arrival to hospital.

We recognise that there are areas within stroke care that have proven particularly challenging and we are committed to continued improvement. We expect health boards to identify aspects of their stroke services which do not meet the Scottish Standards and to work to improve standards of care locally.